Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Fuji
Dow
Daiichi Sankyo
Julphar
McKinsey
Federal Trade Commission
Cerilliant
US Army

Generated: January 17, 2018

DrugPatentWatch Database Preview

Novo Nordisk Inc Company Profile

« Back to Dashboard

Summary for Novo Nordisk Inc
International Patents:464
US Patents:32
Tradenames:49
Ingredients:30
NDAs:40
Drug Master File Entries: 2

Drugs and US Patents for Novo Nordisk Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc FIASP FLEXTOUCH insulin aspart recombinant SOLUTION;SUBCUTANEOUS 208751-002 Sep 29, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLIN N insulin susp isophane semisynthetic purified human INJECTABLE;INJECTION 019065-001 Jan 23, 1985 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-010 Mar 1, 2010 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-011 Jan 23, 2015 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-001 Jun 7, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLIN N insulin susp isophane recombinant human INJECTABLE;INJECTION 019959-001 Jul 1, 1991 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Novo Nordisk Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-002 Nov 25, 2009 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-010 Mar 1, 2010 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NOVOLOG INNOLET insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-004 Apr 23, 2004 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NOVOLOG FLEXTOUCH insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-005 Oct 31, 2013 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-004 Oct 1, 2004 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-006 Oct 1, 2004 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810-001 Aug 26, 2008 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN somatropin recombinant INJECTABLE;INJECTION 019721-002 May 8, 1995 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN somatropin recombinant INJECTABLE;INJECTION 021148-003 Jun 20, 2000 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN somatropin recombinant INJECTABLE;INJECTION 019721-001 May 8, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NOVO NORDISK INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 18 mg/3 mL prefilled syringe ➤ Subscribe 12/12/2016
➤ Subscribe Vaginal Tablets 10 mcg ➤ Subscribe 1/2/2013
➤ Subscribe Tablets 1 mg/500 mg and 2 mg/500 mg ➤ Subscribe 4/9/2009

Non-Orange Book US Patents for Novo Nordisk Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,097,698 Derivatives of GLP-1 analogs ➤ Subscribe
6,011,007 Acylated insulin ➤ Subscribe
9,616,180 Automatic injection device with a top release mechanism ➤ Subscribe
8,096,978 Automatic injection device with a top release mechanism ➤ Subscribe
8,828,923 Insulin derivatives ➤ Subscribe
8,357,120 Injection device with torsion spring and rotatable display ➤ Subscribe
6,869,930 Acylated insulin ➤ Subscribe
7,226,990 Extendin derivatives ➤ Subscribe
6,582,404 Dose setting limiter ➤ Subscribe
6,384,016 Stabilized aqueous peptide solutions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Novo Nordisk Inc Drugs

Supplementary Protection Certificates for Novo Nordisk Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0035 France ➤ Subscribe PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121
2004 00029 Denmark ➤ Subscribe
C015/2004 Ireland ➤ Subscribe SPC015/2004, 20060131, EXPIRES: 20181109
8 5015-2013 Slovakia ➤ Subscribe PRODUCT NAME: INZULIN DEGLUDEK; REGISTRATION NO/DATE: EU/1/12/807/001 - EU/1/12/807/015 20130121
2008013 Lithuania ➤ Subscribe PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
00021 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
C0001 France ➤ Subscribe PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
/2000 Austria ➤ Subscribe PRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623
90029-5 Sweden ➤ Subscribe PRODUCT NAME: INSULIN DEGLUDEK
2012022 Lithuania ➤ Subscribe PRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Johnson and Johnson
Baxter
Cantor Fitzgerald
Express Scripts
Dow
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot